All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99

ViewsDownloads

Relative Articles

Costo directo de la farmacoterapia de la leucemia aguda en el Hospital Clínico Regional de Valdivia, Chile: análisis del período 2003 a 2006

Muerte fetal in utero, etiología y factores asociados en el hospital regional de antofagasta, Chile

Muerte Fetal In útero: Etiología y factores asociados en un Hospital Regional de Antofagasta, Chile

Alta prevalencia de síndrome de Down en el Hospital Regional Rancagua, Chile: Período 1997-2003 High prevalence of Down syndrome in the Rancagua Hospital in central Chile

Long run dynamics of regional growth in Chile.

Alta prevalencia de síndrome de Down en el Hospital Regional Rancagua, Chile: Período 1997-2003

Comparación de susceptibilidad de especies de Shigella a antimicrobianos de uso habitual en el Hospital Regional de Temuco, Chile 1990-2001 Shigella species susceptibility to commonly used antimicrobials in the Temuco Regional Hospital, Chile 1990-2001

Susceptibilidad antimicrobiana de cepas de Pseudomonas aeruginosa aisladas en el laboratoriodel Hospital Regional Dr. Leonardo Guzmán de Antofagasta, Chile

Susceptibilidad antimicrobiana de cepas de Pseudomonas aeruginosa aisladas en el laboratoriodel Hospital Regional Dr. Leonardo Guzmán de Antofagasta, Chile In vitro antimicrobial susceptibility of Pseudomonas aeruginosa strains isolated at Hospital Dr. Leonardo Guzmán, Antofagasta, Chile

Evolución del consumo de antimicrobianos de uso restringido y tendencia de la susceptibilidad in vitro en el Hospital Regional de Concepción, Chile Evolution of use of antibiotics of restricted prescription and trend of bacterial susceptibility in Concepcion Regional Hospital, Chile

More...

Costo directo de la farmacoterapia de la leucemia aguda en el Hospital Clínico Regional de Valdivia, Chile: análisis del período 2003 a 2006 Direct costs of pharmacotherapy for acute leukemia at a Regional Hospital in Chile

Keywords: Antineoplastic protocols , Economics , pharmaceutical , Leukemia

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: In Chile, leukemia is one of the diseases whose treatment is guaranteed by a special law called AUGE (universal access and explicit guaranties). Therefore, the knowledge of its treatment costs is of utmost importance. Aim: To determine and to characterize the direct costs of pharmacotherapy for leukemia at a regional hospital in Chile. Material and methods: Data were retrospectively obtained from electronic and manual records of the hospital for all patients treated for leukemia between 2003 and 2006. Patients were classified into four groups: pediatric and adult patients treated for acute lymphocytic leukemia (ALL children and ALL adults, respectively), and pediatric and adult patients treated for acute myelogenous leukemia (AML children and AML adults, respectively). Results: Total accumulated costs of pharmacotherapy for acute leukemia between 2003 and 2006 were 304,724,845 Chilean pesos (USD 574,952). The higher total or per patient costs, were generated by drugs for chemotherapy compared to other required medications. The exception were AML children, where support drugs, such as antimicrobials, ant emetic drugs and colony stimulating factors, generated the higher costs per patient. Among ALL adults, AML children and AML adults, the costs were concentrated in the first 6 months of treatment. NO children followed this tendency concentrating the costs between the seventh and twenty-fourth months. Conclusions: Annual costs of pharmacotherapy per patient for acute leukemia in this regional hospital were approximately USD 4,717. Chemotherapy was the item with the greatest impact on cost.

Full-Text

comments powered by Disqus